PIK3CA Mutations and Their Coexistence with RAS and BRAF Mutations in Advanced Cancers
Author Information
Author(s): Filip Janku, Lee J. Jack, Tsimberidou Apostolia M., Hong David S., Naing Aung, Falchook Gerald S., Fu Siqing, Luthra Rajyalakshmi, Garrido-Laguna Ignacio, Kurzrock Razelle
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
Do PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers?
Conclusion
PIK3CA mutations are common in various tumors and often coexist with RAS and BRAF mutations.
Supporting Evidence
- 54 (11%) of 504 patients had PIK3CA mutations.
- 69 (19%) of 367 patients had KRAS mutations.
- 19 (8%) of 225 patients had NRAS mutations.
- 31 (9%) of 361 patients had BRAF mutations.
- 47% of patients with PIK3CA mutations had RAS or BRAF mutations.
Takeaway
This study found that many cancer patients have mutations in a gene called PIK3CA, and these mutations often happen together with other mutations in RAS and BRAF genes.
Methodology
Tumor tissues from 504 patients were analyzed for PIK3CA, RAS, and BRAF mutations using DNA sequencing.
Limitations
The study may not cover all cancer types and the sample sizes for some subgroups were small.
Participant Demographics
{"total_patients":504,"gender":{"female":290,"male":214},"median_age":57,"age_distribution":{"<50":142,"50-70":298,">70":64},"ethnicity":{"Caucasian":401,"African American":45,"Hispanic":29,"Asian":29}}
Statistical Information
P-Value
p=0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website